Company intelligence / Profile preview

Immunitas Therapeutics

Waltham, Massachusetts, United States

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Immunitas Therapeutics has advanced its lead program IMT‑009—a first-in-class NK and T cell modulator targeting CD161—into Phase 1/2a clinical trials for patients with refractory solid tumors and lymphomas. The company leverages a proprietary single-cell genomics platform combined with machine learning to identify novel immune targets. Early results have led to significant investment rounds but no published late-stage clinical data yet.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

5 assets

IMT-009

4 more assets in the full pipeline.

Request access →

Partnerships

Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) equity investment; no major pharma partnerships disclosed as of now

Beyond the preview

Go deeper on Immunitas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunitas Therapeutics.

Explore the full profile